Venetoclax-Rituximab in Chronic Lymphocytic Leukemia

Affiliations

¹ Peter MacCallum Cancer Centre, Melbourne, VIC, Australia john.seymour@petermac.org
² Genentech, South San Francisco, CA
³ Academic Medical Center, Amsterdam, the Netherlands

Comment

John F Seymour et al. N Engl J Med. 2018.

. 2018 May 31;378(22):2143-2144.

doi: 10.1056/NEJMc1805135.

¹ Peter MacCallum Cancer Centre, Melbourne, VIC, Australia john.seymour@petermac.org
² Genentech, South San Francisco, CA
³ Academic Medical Center, Amsterdam, the Netherlands

No abstract available

Comment on

Venetoclax-Rituximab in Chronic Lymphocytic Leukemia.
Ferhanoglu B, Ozturk E, Ozbalak M. Ferhanoglu B, et al. N Engl J Med. 2018 May 31;378(22):2141-2. doi: 10.1056/NEJMc1805135. N Engl J Med. 2018. PMID: 29847897 No abstract available.
Venetoclax-Rituximab in Chronic Lymphocytic Leukemia.
Copur MS, Gauchan D, Crockett D. Copur MS, et al. N Engl J Med. 2018 May 31;378(22):2142-3. doi: 10.1056/NEJMc1805135. N Engl J Med. 2018. PMID: 29847898 No abstract available.